Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.
Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).
Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.
Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.
Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:
In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.
The list of potential product benefits includes:
|LN Critical Need||Voclosporin (based on AURA Results)|
|Control of Active Disease|
|Rapid Disease Control|
|Lower Steroid Burden|
|Impact on Extra-renal disease|
|Convenient Treatment Regimen|
In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s
Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.
No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.
|AUPH News: Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022||09/20/2022 04:05:00 PM|
|AUPH News: H.C. Wainwright Sticks to Its Buy Rating for Aurinia Pharmaceuticals (AUPH)||09/20/2022 11:25:06 AM|
|AUPH News: Current Report Filing (8-k)||09/19/2022 04:51:05 PM|
|AUPH News: Aurinia Pharmaceuticals: EC Approved Lupkynis for Active Lupus Nephritis||09/19/2022 12:04:00 PM|
|AUPH News: Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis||09/19/2022 11:15:00 AM|